Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Tempest Therpeutics Inc TPST

Healthcare Biotechnology
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST... see more

Recent & Breaking News (NDAQ:TPST)

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

GlobeNewswire 4 days ago

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

GlobeNewswire 10 days ago

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

GlobeNewswire April 22, 2026

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

GlobeNewswire April 14, 2026

Tempest Reports Year End 2025 Financial Results and Provides Business Update

GlobeNewswire March 30, 2026

Tempest Therapeutics Announces Up To $6 Million Private Placement

GlobeNewswire March 23, 2026

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

GlobeNewswire March 11, 2026

Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

GlobeNewswire February 25, 2026

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

GlobeNewswire February 11, 2026

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

GlobeNewswire February 4, 2026

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

GlobeNewswire January 20, 2026

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

GlobeNewswire November 26, 2025

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

GlobeNewswire November 25, 2025

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

GlobeNewswire November 19, 2025

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 5, 2025

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 11, 2025

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

GlobeNewswire June 30, 2025

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

GlobeNewswire June 11, 2025

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

GlobeNewswire June 5, 2025

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire May 13, 2025

Podcasts